OUR PUBLICATIONS
2024
Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5-10-Year-Old Burkinabe Children Naturally Exposed to Malaria.
Nebie I, Palacpac NMQ, Bougouma EC, Diarra A, Ouédraogo A, D'Alessio F, Houard S, Tiono AB, Cousens S, Horii T, Sirima SB.
Vaccines (Basel). 2024 Feb 6;12(2):166.
2024
Regulatory workshop on challenge strain development and GMP manufacture - A stakeholder meeting report.
Corti N, Chiu C, Cox RJ, Demont C, Devaster JM, Engelhardt OG, Gorringe A, Hassan K, Hoefnagel M, Kamerling I, Krut O, Lane C, Liebers R, Luke C, Van Molle W, Morel S, Neels P, Roestenberg M, Rubbrecht M, Klaas Smits W, Stoughton D, Talaat K, Vehreschild MJGT, Wildfire A, Meln I, Olesen OF.
Biologicals. 2024 Feb;85:101746.
2024
Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics.
Salmanton-García J, Wipfler P, Leckler J, Nauclér P, Mallon PW, Bruijning-Verhagen PCJL, Schmitt HJ, Bethe U, Olesen OF, Stewart FA, Albus K, Cornely OA; VACCELERATE Consortium.
Travel Med Infect Dis. 2024 Jan-Feb;57:102676.
2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium.
Poulimeneas D, Koniordou M, Kousi D, Merakou C, Kopsidas I, Tsopela GC, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Constantinou M, Alexandrou A, Noula E, Nearchou A, Salmanton-García J, Stewart FA, Heringer S, Albus K, Álvarez-Barco E, Macken A, Di Marzo R, Luis C, Valle-Simón P, Askling HH, Hellemans M, Spivak O, Davis RJ, Azzini AM, Barta I, Součková L, Jancoriene L, Akova M, Mallon PWG, Olesen OF, Frias-Iniesta J, van Damme P, Tóth K, Cohen-Kandli M, Cox RJ, Husa P, Nauclér P, Marques L, Ochando J, Tacconelli E, Zeitlinger M, Cornely OA, Pana ZD, Zaoutis TE; VACCELERATE Consortium.
Vaccines (Basel). 2023 Nov 29;11(12):1784.
2023
Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic Escherichia coli (ETEC) and Shigella in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso.
Héma A, Sermé SS, Sawadogo J, Diarra A, Barry A, Ouédraogo AZ, Nébié I, Tiono AB, Houard S, Chakraborty S, Ouédraogo A, Sirima SB.
Microorganisms. 2023 Nov 19;11(11):2809.
2023
Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA.
Doritchamou J, Nielsen MA, Chêne A, Viebig NK, Lambert LE, Sander AF, Semblat JP, Hundt S, Orr-Gonzalez S, Janitzek CM, Spiegel AJ, Clemmensen SB, Thomas ML 3rd, Nason MC, Snow-Smith M, Barnafo EK, Shiloach J, Chen BB, Nadakal S, Highsmith K, Ouahes T, Conteh S, Sharma A, Torano H, Butler B, Reiter K, Rausch KM, Scaria PV, Anderson C, Narum DL, Salanti A, Fried M, Theander TG, Gamain B, Duffy PE.
Lab Anim (NY). 2023 Dec;52(12):315-323.
2023
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time.
Kenny G, O'Reilly S, Wrigley Kelly N, Negi R, Gaillard C, Alalwan D, Saini G, Alrawahneh T, Francois N, Angeliadis M, Garcia Leon AA, Tinago W, Feeney ER, Cotter AG, de Barra E, Yousif O, Horgan M, Doran P, Stemler J, Koehler P, Cox RJ, O'Shea D, Olesen OF, Landay A, Hogan AE, Lelievre JD, Gautier V, Cornely OA, Mallon PWG; All Ireland Infectious Diseases Cohort Study; VACCELERATE Consortium EU-COVAT-1-AGED Part A Study Group.
Nat Commun. 2023 Nov 2;14(1):7015.
2023
Vaccine Hesitancy among Healthcare Workers in Europe: A Systematic Review.
Kaur M, Coppeta L, Olesen OF.
Vaccines (Basel). 2023 Oct 28;11(11):1657.
2023
Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact.
Jungbluth S, Martin W, Slezak M, Depraetere H, Guzman CA, Ussi A, Morrow D, Van Heuverswyn F, Arnouts S, Carrondo MJT, Olesen O, Ottenhoff THM, Dockrell HM, Ho MM, Dobly A, Christensen D, Segalés J, Laurent F, Lantier F, Stockhofe-Zurwieden N, Morelli F, Langermans JAM, Verreck FAW, Le Grand R, Sloots A, Medaglini D, Lawrenz M, Collin N.
F1000Res. 2023 Oct 24;12:1401.
2023
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Ouédraogo A, Bougouma EC, Palacpac NMQ, Houard S, Nebie I, Sawadogo J, Berges GD, Soulama I, Diarra A, Hien D, Ouedraogo AZ, Konaté AT, Kouanda S, Myoui A, Ezoe S, Ishii KJ, Sato T, D'Alessio F, Leroy O, Tiono AB, Cousens S, Horii T, Sirima SB.
Front Immunol. 2023 Oct 16;14:1267372.